Stock Track | Becton Dickinson Plummets 5.43% as Separation Plan and Guidance Cut Disappoint Investors

Stock Track

Feb 07, 2025

Shares of Becton Dickinson (NYSE: BDX) plummeted 5.43% in the intraday trading session, after the medical technology company announced plans to separate its Biosciences and Diagnostic Solutions business, while also lowering its fiscal 2025 revenue guidance.

According to the company, the planned separation aims to enhance strategic focus and enable growth-oriented investments and capital allocation for the two businesses. After the separation, the New BD will be a pure-play medical technology company with expected fiscal 2024 revenue of approximately $17.8 billion, while the Biosciences and Diagnostic Solutions business is expected to have around $3.4 billion in revenue.

Meanwhile, Becton Dickinson lowered its fiscal 2025 revenue guidance from the previous range of $21.9 billion to $22.1 billion to a new range of $21.7 billion to $21.9 billion, which fell short of analysts' consensus estimate of $21.93 billion. However, the company raised its adjusted EPS guidance range to $14.30 to $14.60, up from the previous range of $14.25 to $14.60.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1126690999"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126690999\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126690999?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-07 01:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126690999","market":"hk","top_or_hot":-1,"title":"Stock Track | Becton Dickinson Plummets 5.43% as Separation Plan and Guidance Cut Disappoint Investors","media":"Stock Track","content":"<p>Shares of Becton Dickinson (NYSE: BDX) plummeted 5.43% in the intraday trading session, after the medical technology company announced plans to separate its Biosciences and Diagnostic Solutions business, while also lowering its fiscal 2025 revenue guidance.</p>\n\n<p>According to the company, the planned separation aims to enhance strategic focus and enable growth-oriented investments and capital allocation for the two businesses. After the separation, the New BD will be a pure-play medical technology company with expected fiscal 2024 revenue of approximately $17.8 billion, while the Biosciences and Diagnostic Solutions business is expected to have around $3.4 billion in revenue.</p>\n\n<p>Meanwhile, Becton Dickinson lowered its fiscal 2025 revenue guidance from the previous range of $21.9 billion to $22.1 billion to a new range of $21.7 billion to $21.9 billion, which fell short of analysts' consensus estimate of $21.93 billion. However, the company raised its adjusted EPS guidance range to $14.30 to $14.60, up from the previous range of $14.25 to $14.60.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Becton Dickinson Plummets 5.43% as Separation Plan and Guidance Cut Disappoint Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Becton Dickinson Plummets 5.43% as Separation Plan and Guidance Cut Disappoint Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-07 01:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Becton Dickinson (NYSE: BDX) plummeted 5.43% in the intraday trading session, after the medical technology company announced plans to separate its Biosciences and Diagnostic Solutions business, while also lowering its fiscal 2025 revenue guidance.</p>\n\n<p>According to the company, the planned separation aims to enhance strategic focus and enable growth-oriented investments and capital allocation for the two businesses. After the separation, the New BD will be a pure-play medical technology company with expected fiscal 2024 revenue of approximately $17.8 billion, while the Biosciences and Diagnostic Solutions business is expected to have around $3.4 billion in revenue.</p>\n\n<p>Meanwhile, Becton Dickinson lowered its fiscal 2025 revenue guidance from the previous range of $21.9 billion to $22.1 billion to a new range of $21.7 billion to $21.9 billion, which fell short of analysts' consensus estimate of $21.93 billion. However, the company raised its adjusted EPS guidance range to $14.30 to $14.60, up from the previous range of $14.25 to $14.60.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BDX","symbol_name":"碧迪医疗","start_time":0,"source_url":"","article_id":"1126690999","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126690999","pubTimestamp":1738864278,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Becton Dickinson  plummeted 5.43% in the intraday trading session, after the medical technology company announced plans to separate its Biosciences and Diagnostic Solutions business, while also lowering its fiscal 2025 revenue guidance.According to the company, the planned separation aims to enhance strategic focus and enable growth-oriented investments and capital allocation for the two businesses. After the separation, the New BD will be a pure-play medical technology company with ex","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BDX":"碧迪医疗"},"translate_title":"由于分离计划和指导削减令投资者失望，Becton Dickinson股价暴跌5.43%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDX":1},"content_text":"Shares of Becton Dickinson (NYSE: BDX) plummeted 5.43% in the intraday trading session, after the medical technology company announced plans to separate its Biosciences and Diagnostic Solutions business, while also lowering its fiscal 2025 revenue guidance.\nAccording to the company, the planned separation aims to enhance strategic focus and enable growth-oriented investments and capital allocation for the two businesses. After the separation, the New BD will be a pure-play medical technology company with expected fiscal 2024 revenue of approximately $17.8 billion, while the Biosciences and Diagnostic Solutions business is expected to have around $3.4 billion in revenue.\nMeanwhile, Becton Dickinson lowered its fiscal 2025 revenue guidance from the previous range of $21.9 billion to $22.1 billion to a new range of $21.7 billion to $21.9 billion, which fell short of analysts' consensus estimate of $21.93 billion. However, the company raised its adjusted EPS guidance range to $14.30 to $14.60, up from the previous range of $14.25 to $14.60.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}